Liver natural killer cells play a role in the destruction of islets after intraportal transplantation

Transplantation

Volumn 91, Issue 9, 2011, Pages 952-960

  Ishiyama, Kohei ^a   Rawson, Jeffrey ^a   Omori, Keiko ^a   Mullen, Yoko ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Cytotoxicity; Islet transplantation; Liver; Natural killer cells

Indexed keywords

GANGLIOSIDE GM1 ANTIBODY;

ALLOGRAFT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; C57BL 6 MOUSE; CELL DAMAGE; CONTROLLED STUDY; CYTOTOXICITY; DIABETES MELLITUS; GRAFT FAILURE; GRAFT RECIPIENT; HYPERGLYCEMIA; IN VIVO STUDY; ISOGRAFT; LIVER CELL; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DEPLETION; LYMPHOCYTE FUNCTION; MALE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PANCREAS ISLET BETA CELL; PANCREAS ISLET TRANSPLANTATION; PHENOTYPE; PRIORITY JOURNAL; SPLEEN CELL;

ANIMALS; CYTOTOXICITY, IMMUNOLOGIC; DIABETES MELLITUS, EXPERIMENTAL; GRAFT SURVIVAL; HUMANS; IMMUNITY, INNATE; INTERFERON-GAMMA; ISLETS OF LANGERHANS TRANSPLANTATION; KILLER CELLS, NATURAL; LIVER; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DEPLETION; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; SPLEEN; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSPLANTATION, HOMOLOGOUS; TRANSPLANTATION, ISOGENEIC; UP-REGULATION;

EID: 79955549134     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3182139dc1     Document Type: Article

References (51)

1. Ricordi C, Strom TB. Clinical islet transplantation: Advances and immunological challenges. Nat Rev Immunol 2004; 4: 259.
2. Merani S, Toso C, Emamaullee J, et al. Optimal implantation site for pancreatic islet transplantation. Br J Surg 2008; 95: 1449.
3. van der Windt DJ, Echeverri GJ, Ijzermans JN, et al. The choice of anatomical site for islet transplantation. Cell Transplant 2008; 17: 1005.
4. Rajab A. Islet transplantation: Alternative sites. Curr Diab Rep 2010; 10: 332.
5. Jones GL, Juszczak MT, Hughes SJ, et al. Time course and quantification of pancreatic islet revascularization following intraportal transplantation. Cell Transplant 2007; 16: 505.
6. Hyon SH, Ceballos MC, Barbich M, et al. Effect of the embolization of completely unpurified islets on portal vein pressure and hepatic biochemistry in clinical practice. Cell Transplant 2004; 13: 61.
7. Toyofuku A, Yasunami Y, Nabeyama K, et al. Natural killer T-cells participate in rejection of islet allografts in the liver of mice. Diabetes 2006; 55: 34.
8. Yin D, Ding JW, Shen J, et al. Liver ischemia contributes to early islet failure following intraportal transplantation: Benefits of liver ischemicpreconditioning. Am J Transplant 2006; 6: 60.
9. Bottino R, Fernandez LA, Ricordi C, et al. Transplantation of allogeneic islets of Langerhans in the rat liver: Effects of macrophage depletion on graft survival and microenvironment activation. Diabetes 1998; 47: 316.
10. Karlsson-Parra A, Ridderstad A, Wallgren AC, et al. Xenograft rejection of porcine islet-like cell clusters in normal and natural killer celldepleted mice. Transplantation 1996; 61: 1313.
11. Wu G, Korsgren O, Zhang J, et al. Pig islet xenograft rejection is markedly delayed in macrophage-depleted mice: A study in streptozotocin diabetic animals. Xenotransplantation 2000; 7: 214.
12. Trinchieri G. Biology of natural killer cells. Adv Immunol 1989; 47: 187.
13. Gao B, Jeong WI, Tian Z. Liver: An organ with predominant innate immunity. Hepatology 2008; 47: 729.
14. Kita H, Mackay IR, Van De Water J, et al. The lymphoid liver: Considerations on pathways to autoimmune injury. Gastroenterology 2001; 120: 1485.
15. Seki S, Habu Y, Kawamura T, et al. The liver as a crucial organ in the first line of host defense: The roles of Kupffer cells, natural killer (NK) cells and NK1.1 Ag-T cells in T helper 1 immune responses. Immunol Rev 2000; 174: 35.
16. Ochi M, Ohdan H, Mitsuta H, et al. Liver NK cells expressing TRAIL are toxic against self hepatocytes in mice. Hepatology 2004; 39: 1321.
17. Ishiyama K, Ohdan H, Ohira M, et al. Difference in cytotoxicity against hepatocellular carcinoma between liver and periphery natural killer cells in humans. Hepatology 2006; 43: 362.
18. Ohira M, Ohdan H, Mitsuta H, et al. Adoptive transfer of TRAILexpressing natural killer cells prevents recurrence of hepatocellular carcinoma after partial hepatectomy. Transplantation 2006; 82: 1712.
19. Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends Immunol 2001; 22: 633.
20. Caligiuri MA. Human natural killer cells. Blood 2008; 112: 461.
21. Trambley J, Bingaman AW, Lin A, et al. Asialo GM1 CD8 T cells play a critical role in costimulation blockade-resistant allograft rejection. J Clin Invest 1999; 104: 1715.
22. Pitti RM, Marsters SA, Ruppert S, et al. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 1996; 271: 12687.
23. Shapiro AM, Lakey JR, Ryan EA, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000; 343: 230.
24. Ryan EA, Paty BW, Senior PA, et al. Five-year follow-up after clinical islet transplantation. Diabetes 2005; 54: 2060.
25. Shapiro AM, Ricordi C, Hering BJ, et al. International trial of the Edmonton protocol for islet transplantation. N Engl J Med 2006; 355: 1318.
26. Ryan EA, Lakey JR, Rajotte RV, et al. Clinical outcomes and insulin secretion after islet transplantation with the Edmonton protocol. Diabetes 2001; 50: 710.
27. Korsgren O, Lundgren T, Felldin M, et al. Optimising islet engraftment is critical for successful clinical islet transplantation. Diabetologia 2008; 51: 227.
28. Evgenov NV, Medarova Z, Pratt J, et al. In vivo imaging of immune rejection in transplanted pancreatic islets. Diabetes 2006; 55: 2419.
29. Davalli AM, Scaglia L, Zangen DH, et al. Vulnerability of islets in the immediate posttransplantation period. Dynamic changes in structure and function. Diabetes 1996; 45: 1161.
30. Hughes SJ, Davies SE, Powis SH, et al. Hyperoxia improves the survival of intraportally transplanted syngeneic pancreatic islets. Transplantation 2003; 75: 1954.
31. Eich T, Eriksson O, Sundin A, et al. Positron emission tomography: A real-time tool to quantify early islet engraftment in a preclinical large animal model. Transplantation 2007; 84: 893.
32. Sakata N, Tan A, Chan N, et al. Efficacy comparison between intraportal and subcapsular islet transplants in a murine diabetic model. Transplant Proc 2009; 41: 346.
33. Kaufman DB, Platt JL, Rabe FL, et al. Differential roles of Mac-1-cells, and CD4 and CD8 T lymphocytes in primary nonfunction and classic rejection of islet allografts. J Exp Med 1990; 172: 291.
34. Chahine AA, Stoeckert C, Lau HT. Local immunomodulation to promote co-stimulatory blockade. Clin Transplant 1995; 9(3 Pt 2): 215
35. Tripathy SK, Keyel PA, Yang L, et al. Continuous engagement of a self-specific activation receptor induces NK cell tolerance. J Exp Med 2008; 205: 1829.
36. Vivier E, Tomasello E, Baratin M, et al. Functions of natural killer cells. Nat Immunol 2008; 9: 503.
37. Hallett WH, Murphy WJ. Positive and negative regulation of natural killer cells: Therapeutic implications. Semin Cancer Biol 2006; 16: 367.
38. Sheridan JP, Marsters SA, Pitti RM, et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 1997; 277: 818.
39. Pan G, O'Rourke K, Chinnaiyan AM, et al. The receptor for the cytotoxic ligand TRAIL. Science 1997; 276: 111.
40. Kayagaki N, Yamaguchi N, Nakayama M, et al. Expression and function of TNF-related apoptosis-inducing ligand on murine activatedNK cells. J Immunol 1999; 163: 1906.
41. Matsuda T, Omori K, Vuong T, et al. Inhibition of p38 pathway suppresses human islet production of pro-inflammatory cytokines and improves islet graft function. Am J Transplant 2005; 5: 484.
42. Lapaque N, Walzer T, Meresse S, et al. Interactions between humanNK cells and macrophages in response to Salmonella infection. J Immunol 2009; 182: 4339.
43. Baratin M, Roetynck S, Lepolard C, et al. Natural killer cell and macrophage cooperation in MyD88-dependent innate responses to Plasmodium falciparum. Proc Natl Acad Sci U S A 2005; 102: 14747.
44. Dugast AS, Vanhove B. Immune regulation by non-lymphoid cells in transplantation. Clin Exp Immunol 2009; 156: 25.
45. Spaggiari GM, Capobianco A, Abdelrazik H, et al. Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: Role of indoleamine 2,3-dioxygenase and prostaglandin E2. Blood 2008; 111: 1327.
46. Sotiropoulou PA, Perez SA, Gritzapis AD, et al. Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells 2006; 24: 74.
47. Bouwens L, Remels L, Baekeland M, et al. Large granular lymphocytes or "pit cells" from rat liver: Isolation, ultrastructural characterization and natural killer activity. Eur J Immunol 1987; 17: 37.
48. Kemp CB, Knight MJ, Scharp DW, et al. Transplantation of isolated pancreatic islets into the portal vein of diabetic rats. Nature 1973; 244: 447.
49. Yasunami Y, Lacy PE, Davie JM, et al. Prolongation of islet xenograft survival (rat to mouse) by in vitro culture at 37°C. Transplantation 1983; 35: 281.
50. Jedema I, van der Werff NM, Barge RM, et al. New CFSE-based assay to determine susceptibility to lysis by cytotoxic T cells of leukemic precursor cells within a heterogeneous target cell population. Blood 2004; 103: 2677.
51. Tanaka Y, Ohdan H, Onoe T, et al. Multiparameter flow cytometric approach for simultaneous evaluation of proliferation and cytokinesecreting activity in T cells responding to allo-stimulation. Immunol Invest 2004; 33: 309.